NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

Info Session: Information Session on Civil Security for Society and European Defence Fund

 Pick a topic from the menu to get started.

On July 7th 2022, NCP Flanders organised an info session on security-related topics within the European Defence FundHorizon Europe (Civil Security for Society) and Digital Europe (Cybersecurity).

The session aims to provide an overview on funding opportunities for researchers, companies and practitioners.

Agenda:

  1. Introduction – Mark Antonissen, NCP Flanders
    European Defence Fund – Mark Antonissen, NCP Flanders
  2. Horizon Europe: Civil Security in Society (Cluster 3) & Digital Europe: Cybersecurity - Marie Timmermann, NCP Flanders
  3. Development of work programmes - Paris Van Paesschen, Department of Economics, Science & Innovation (Departement EWI)

 Pick a topic from the menu to get started.

Testimonial

image of BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

BEAT-AF - Ground-Breaking Electroporation-based intervention for Atrial Fibrillation treatment

The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.